Irrigone-BLS Tablet contains Bilastine 20 mg, a second-generation antihistamine indicated for the symptomatic treatment of allergic conditions such as seasonal allergic rhinitis, perennial allergic rhinitis, and chronic urticaria. Bilastine selectively antagonizes peripheral H1 histamine receptors, thereby inhibiting the effects of endogenous histamine responsible for allergic symptoms including sneezing, nasal congestion, rhinorrhea, pruritus, and urticaria-associated itching and wheals. Due to its high selectivity and minimal penetration of the blood-brain barrier, Bilastine is associated with a low incidence of sedation and central nervous system side effects compared to first-generation antihistamines. The recommended dosage is one 20 mg tablet once daily, with or without food, ensuring optimal efficacy and patient compliance. Bilastine is rapidly absorbed, reaching peak plasma concentrations within 1 hour, and exhibits a half-life conducive to once-daily dosing. It is metabolized minimally, reducing the risk of drug interactions. Caution is advised in patients with severe renal impairment, and use during pregnancy or lactation should be under medical supervision. Irrigone-BLS Tablet offers effective relief from allergic symptoms with a favorable safety profile, making it a valuable option in the management of allergic disorders.